TICKERNERD
Menu
UTMDUTMDHealthcare · Medical Instruments & Supplies

UTMD Stock Forecast: Utah Medical Products, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$74
−0.31% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 19 Sept 2026 — inside the top quartile.

Market cap
$235.5M
Ticker Nerd rank
79 / 100
Median analyst target
—
Analysts covering
0
Revenue$8.5M−14.3% y/y
Operating income$2.6M
Net income$2.7M
Free cash flow$1.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.6%
1M
+3.2%
YTD
+34.0%
1Y
+18.9%
From 52W high
−0.5%
From 52W low
+40.2%
$53
$74
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

UTMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Utah Medical Products, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Momentum
90
Issuance
85
Value
77
Size
66
Quality
62
Accruals
51
Growth
49
Revisions
25

Volatility (98): The share price has been relatively steady.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

UTMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on UTMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$55$60$65$70$75Oct 25Jan 26Apr 26Jul 26UTMD

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. UTMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

UTMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Utah Medical Products, Inc. returned +18.9% against +16.3% for the S&P 500, dividends included.

UTMD vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Oct 25Jan 26Apr 26Jul 26UTMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

UTMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Utah Medical Products, Inc. (UTMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
22.5×

Cheaper than 33% of US stocks

Price / sales
6.5×

Cheaper than 20% of US stocks

Price / book
2.0×

Cheaper than 46% of US stocks

EV / EBITDA
10.3×

Cheaper than 37% of US stocks

Growth & margins
Revenue growth (YoY)
−14.3%

Higher than 13% of US stocks

Earnings growth (YoY)
−11.9%

Higher than 25% of US stocks

Gross margin
55.8%

Higher than 69% of US stocks

Operating margin
36.9%

Higher than 90% of US stocks

Net margin
29.0%

Higher than 88% of US stocks

Returns & dividend
Return on equity
8.8%

Higher than 60% of US stocks

Return on assets
6.1%

Higher than 81% of US stocks

Dividend yield
1.7%

Higher than 38% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Utah Medical Products, Inc. (UTMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Utah Medical Products, Inc. has a market value of $235.5M and an enterprise value of $148.1M.

  • Revenue in the twelve months to 30 June 2026: $36.1M. The latest quarter shrank 14.3% year on year.

  • Net income over the same four quarters: $10.5M, a 29.0% net margin.

  • Diluted earnings per share, trailing twelve months: $3.28.

  • Free cash flow in the twelve months to 30 June 2026: $11.4M.

  • Utah Medical Products, Inc. spent $1.9M on share buybacks and $3.9M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 3.2M.

  • Trailing P/E: 22.5×.

  • Forward dividend yield: 1.67%, paying out 38% of earnings.

  • Utah Medical Products, Inc. employs 140 people — $258K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

UTMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
UTMDUtah Medical Products, Inc.$235.5M
79
PDEXPro-Dex, Inc.$231.6M
94
OSUROraSure Technologies, Inc.$246.1M
89
EMBCEmbecta Corp.$313.3M
84
SMTISanara MedTech, Inc.$322.2M
92
ZJYLJin Medical International Ltd.$156.1M
17
KRMDKORU Medical Systems, Inc.$148.4M
95

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Utah Medical Products, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest UTMD news & analysis

UTMD Announces Self-Tender for 20% of Its Shares

Accesswire · 15 Sept 2026positive

Utah Medical Products, Inc. announced a self-tender offer to repurchase up to 650,000 of its shares, approximately 20% of its outstanding shares, at $75.00 per share, with tenders due by October 7. The offering price is 17% higher than the average daily closing price over the past year and 21% higher than over the past two years.

Why it matters — A significant self-tender at a premium to recent market prices signals management's confidence in the company's value and offers stockholders a potential opportunity to sell shares at above-market prices.

Femcare Ltd Acquires Orion Medical Supplies Ltd in the UK

Accesswire · 31 Aug 2026positive

Femcare Ltd, a wholly-owned subsidiary of Utah Medical Products, Inc., announced that it has purchased the entire ordinary share capital of Orion Medical Supplies Ltd, a UK-based company.

Why it matters — This acquisition expands Utah Medical Products' presence and operations in the UK market through its subsidiary Femcare.

Utah Medical Products, Inc. Announces Quarterly Dividend

Accesswire · 4 Aug 2026positive

Utah Medical Products announced that its Board of Directors approved a quarterly cash dividend of $0.31 per share, payable October 5, 2026 to stockholders of record on September 17, 2026. The dividend represents a 1.6% increase over the dividend declared in the same quarter of the prior year.

Why it matters — A UTMD watcher would care because the company maintained its shareholder payout with a year-over-year increase in the declared quarterly dividend.

Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses

Zacks Investment Research · 29 July 2026negative

Utah Medical Products reported Q2 earnings per share down 10.1% year over year, with quarterly revenues facing pressure from lost customers and slower new business growth.

Why it matters — This signals potential headwinds to UTMD's revenue and earnings momentum, which could affect the company's financial performance and shareholder returns.

FAQ

Frequently asked questions about UTMD stock

How does Ticker Nerd's model rank UTMD?

As at 19 Sept 2026, Utah Medical Products, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

What is the UTMD stock forecast for 2030?

No analyst covering Utah Medical Products, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UTMD are extrapolating price history, which says nothing about the business.

How has UTMD stock performed over the past year?

Utah Medical Products, Inc. returned +18.9% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Utah Medical Products, Inc. do?

Utah Medical Products, Inc. is a medical device company that develops, manufactures, and markets specialized disposable and reusable products for healthcare settings.

What is the latest news on UTMD?

The most recent item we track (Accesswire, 15 Sept 2026): "UTMD Announces Self-Tender for 20% of Its Shares". Utah Medical Products, Inc. announced a self-tender offer to repurchase up to 650,000 of its shares, approximately 20% of its outstanding shares, at $75.00 per share, with tenders due by October 7. The offering price is 17% higher than the average daily closing price over the past year and 21% higher than over the past two years.

Company

About Utah Medical Products, Inc.

Utah Medical Products, Inc. is a medical device company that develops, manufactures, and markets specialized disposable and reusable products for healthcare settings. The company focuses on women’s and babies’ health, with offerings used in obstetrics, gynecology, neonatal care, perinatology, urology, blood pressure monitoring, and blood collection. Its product portfolio includes labor and delivery tools, fetal monitoring accessories, vacuum-assisted delivery systems, infant respiratory hoods, and electrosurgical devices. Utah Medical Products serves hospitals, clinics, and other medical facilities that require procedure-specific devices designed for clinical use and patient safety. Headquartered in Midvale, Utah, the company operates as a focused supplier within the broader medical instruments and supplies market, with products distributed across domestic and international healthcare markets.

CEO Mr. Kevin L. Cornwell · 140 employees · United States · https://www.utahmed.com